regulatory subunit of phosphoinositide-3-kinase. Mediates binding to a subset of tyrosine-phosphorylated proteins through its SH2 domain. Acts as an adapter, mediating the association of the p110 catalytic unit of the alpha, beta and delta enzymes to the plasma membrane, where p110 phosphorylates inositol lipids. May play an additional role in the regulation of the actin cytoskeleton. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Its SH2 domains interacts with the YTHM motif of phosphorylated INSR in vitro. Defects in PIK3R1 are a cause of severe insulin resistance. Four alternatively spliced isoforms have been described. Note: This description may include information from UniProtKB.
Protein type: Motility/polarity/chemotaxis; Enzyme, regulatory subunit; Kinase, lipid
Molecular Function: protein C-terminus binding; protein domain specific binding; 1-phosphatidylinositol-3-kinase activity; neurotrophin TRKA receptor binding; platelet-derived growth factor receptor binding; phosphoprotein binding; 1-phosphatidylinositol-3-kinase regulator activity; phosphoinositide 3-kinase regulator activity; receptor tyrosine kinase binding; transcription factor binding; protein phosphatase binding; protein kinase binding; ATPase binding; insulin receptor binding; insulin binding; calmodulin binding; insulin-like growth factor receptor binding; protein binding; ErbB-3 class receptor binding; protein heterodimerization activity; ubiquitin protein ligase binding; insulin receptor substrate binding; phosphoinositide 3-kinase binding; estrogen receptor binding; receptor binding
Biological Process: negative regulation of osteoclast differentiation; phosphoinositide 3-kinase cascade; response to cAMP; negative regulation of heart rate; negative regulation of smooth muscle cell proliferation; response to glucocorticoid stimulus; signal transduction; positive regulation of RNA splicing; protein amino acid phosphorylation; regulation of phosphoinositide 3-kinase activity; NFAT protein import into nucleus; response to insulin stimulus; protein transport; transport; phosphoinositide phosphorylation; positive regulation of transcription factor import into nucleus; negative regulation of blood pressure; negative regulation of proteolysis; protein stabilization; glucose metabolic process; negative regulation of cell-matrix adhesion; positive regulation of tumor necrosis factor production; positive regulation of myoblast differentiation; cellular response to insulin stimulus; insulin-like growth factor receptor signaling pathway; induction of apoptosis via death domain receptors; DNA damage response, signal transduction resulting in induction of apoptosis; B cell differentiation; insulin receptor signaling pathway; cell glucose homeostasis; positive regulation of transcription from RNA polymerase II promoter; positive regulation of protein amino acid phosphorylation; negative regulation of cell-cell adhesion; negative regulation of apoptosis; positive regulation of cell migration
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.